Miriam R. Brezis, S. P. Hasson, E. Shachar, D. Grisaro, I. Laskov, N. Michaan, L. Adar, Avigail Harpaz, Adi Diner, Bar Levy, I. Wolf, T. Safra
{"title":"2022-RA-209-ESGO A retrospective study of ovarian cancer among elderly – evaluation and prognosis","authors":"Miriam R. Brezis, S. P. Hasson, E. Shachar, D. Grisaro, I. Laskov, N. Michaan, L. Adar, Avigail Harpaz, Adi Diner, Bar Levy, I. Wolf, T. Safra","doi":"10.1136/ijgc-2022-esgo.483","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.483","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"130 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74117972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Nguyen, B. N. Santana, G. Babin, S. Forte, Mathilde Mairé, F. Guyon
{"title":"2022-VA-572-ESGO Hudson posterior exenteration, with the use of ICG fluorescence to assess rectal anastomosis and ureteral integrity","authors":"D. Nguyen, B. N. Santana, G. Babin, S. Forte, Mathilde Mairé, F. Guyon","doi":"10.1136/ijgc-2022-esgo.515","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.515","url":null,"abstract":"The proposed test is a viable alternative to the Myriad myChoice HRD test and can easily be implemented in a clinical laboratory for routine practice. The performance of the tests is similar in terms of hazard ratio but the lower fail-ure rate of the Geneva HRD test allows a 10% increase in the number of patients receiving a conclusive laboratory result.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75273692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"2022-RA-1140-ESGO Rare ovarian tumors not a rarity anymore","authors":"A. Singla, R. Aggarwal","doi":"10.1136/ijgc-2022-esgo.649","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.649","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72661173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Andrikopoulou, K. Apostolidou, C. Theofanakis, C. Markellos, Efthymia Skafida, O. Fiste, M. Kaparelou, K. Koutsoukos, N. Thomakos, D. Haidopoulos, A. Rodolakis, F. Zagouri, M. Dimopoulos, M. Liontos
{"title":"2022-RA-1607-ESGO Optimal time interval between neoadjuvant platinum-based chemotherapy and interval debulking surgery","authors":"A. Andrikopoulou, K. Apostolidou, C. Theofanakis, C. Markellos, Efthymia Skafida, O. Fiste, M. Kaparelou, K. Koutsoukos, N. Thomakos, D. Haidopoulos, A. Rodolakis, F. Zagouri, M. Dimopoulos, M. Liontos","doi":"10.1136/ijgc-2022-esgo.755","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.755","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76480934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Laios, E. Kalampokis, R. Johnson, S. Munot, R. Hutson, A. Thangavelu, T. Broadhead, G. Theophilou, D. Nugent, D. Dejong
{"title":"2022-RA-1675-ESGO Development of an intra-operative disease score to predict complete cytoreduction in advanced-stage ovarian cancer by using artificial intelligence","authors":"A. Laios, E. Kalampokis, R. Johnson, S. Munot, R. Hutson, A. Thangavelu, T. Broadhead, G. Theophilou, D. Nugent, D. Dejong","doi":"10.1136/ijgc-2022-esgo.773","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.773","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"511 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80086545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Musacchio, V. Salutari, S. Pignata, G. Valabrega, L. Zavallone, G. Cormio, A. Mosconi, S. Giolitto, E. Giudice, C. Ricci, C. Zamagni, C. Nero, M. V. Carbone, V. Ghizzoni, R. Sorio, S. Siena, F. Tronconi, A. Savarese, G. Scambia, D. Lorusso
{"title":"2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary perito","authors":"L. Musacchio, V. Salutari, S. Pignata, G. Valabrega, L. Zavallone, G. Cormio, A. Mosconi, S. Giolitto, E. Giudice, C. Ricci, C. Zamagni, C. Nero, M. V. Carbone, V. Ghizzoni, R. Sorio, S. Siena, F. Tronconi, A. Savarese, G. Scambia, D. Lorusso","doi":"10.1136/ijgc-2022-esgo.739","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.739","url":null,"abstract":"Introduction/Background The discrimination of borderline ovarian tumor (BOT) is challenging Ultrasonography (US) is the most essential imaging modality for distinguishing ovarian masses but depends on the experience of radiologists. In 2014, the IOTA group carried out the assessment of different neoplasia’s in the Adnex Model. It was used to discriminate benign, BOTs, stage I, stage II-IV invasive ovarian cancer, and secondary metastatic cancer. This study aims to evaluate the efficacy of the Adnex model in the determination of BOTs. Methodology This was a retrospective study, medical records of histopathologically proven cases of BOTs were included from the year 2009 to 2021. The ultrasound and clinical findings were entered in an online Adnex calculator. These results were used to calculate the absolute risk predicting the probability of mass being as BOT. Results A total of 22 cases of BOT were included. Efficacy in terms of sensitivity of the Adnex model for preoperative diagnosis of BOTs was 18.2% [95%CI: 7.31–38.52]. Performance of the Adnex model based on absolute risk (AR) improves with a selection of a more inclusive cut-off value, varying from 4.5% (1/22) correctly classified case of BOT with the cut-off 20%,18.2% (4/22) with the cut-off 10% and up to 55.5% (12/22) classified cases of BOT with cut off value of 3%. Similarly, relative risk (RR)was also used to classify the BOT, but only 4(18.2%) cases were identified correctly. Conclusion More encompassing cut-off values allow the model to differentiate BOTs better. The calculation based on RR or AR with a cut-off value of at least 10% should be used when evaluating BOTs.The IOTA Adnex model did not perform well in predicting cases of BOTs that were histopathologically proven in terms of sensitivity.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81693959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clara E Goerdt, D. Bokhua, V. Auletta, A. Kather, I. Runnebaum
{"title":"2022-RA-1101-ESGO Prediction of incomplete cytoreduction in primary debulking surgery of advanced stage ovarian cancer patients: Usefulness of the entire peritoneal cancer index (PCI) versus exclusive assessment of small intestine/mesentery/hepatoduodenal ligament carcinosis","authors":"Clara E Goerdt, D. Bokhua, V. Auletta, A. Kather, I. Runnebaum","doi":"10.1136/ijgc-2022-esgo.634","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.634","url":null,"abstract":"may be useful radiological markers of poor prognosis to support clinical decision-making when considering HPN","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84267948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Bizzarri, M. Imterat, R. Fruscio, A. Perrone, R. Mancari, A. Traut, A. Rosati, A. Bois, D. Ferrari, P. De Iaco, R. Ergasti, B. Ataseven, S. Volonte’, M. Tesei, M. Perri, F. Heitz, N. Concin, F. Fanfani, E. Vizza, G. Scambia, P. Harter, A. Fagotti
{"title":"2022-RA-1515-ESGO Impact of surgical staging on survival of low grade endometrioid ovarian cancer apparently confined to the ovary","authors":"N. Bizzarri, M. Imterat, R. Fruscio, A. Perrone, R. Mancari, A. Traut, A. Rosati, A. Bois, D. Ferrari, P. De Iaco, R. Ergasti, B. Ataseven, S. Volonte’, M. Tesei, M. Perri, F. Heitz, N. Concin, F. Fanfani, E. Vizza, G. Scambia, P. Harter, A. Fagotti","doi":"10.1136/ijgc-2022-esgo.733","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.733","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85877033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Kujawa, E. Zembala-Nożyńska, J. Syrkis, A. Cortez, J. Kupryjańczyk, K. Lisowska
{"title":"2022-RA-1112-ESGO MFAP5 is related to ovarian cancer progression but not suitable as prognostic biomarker","authors":"K. Kujawa, E. Zembala-Nożyńska, J. Syrkis, A. Cortez, J. Kupryjańczyk, K. Lisowska","doi":"10.1136/ijgc-2022-esgo.641","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.641","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76899731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adam Naskretski, Susan Prosser, G. Owens, S. Jones
{"title":"2022-RA-1565-ESGO Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for metastatic ovarian cancer, fallopian tube cancer and primary peritoneal carcinoma: a systematic review by the UK PIPAC collaborative","authors":"Adam Naskretski, Susan Prosser, G. Owens, S. Jones","doi":"10.1136/ijgc-2022-esgo.747","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.747","url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77044116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}